中国肿瘤生物治疗杂志2025，Vol.32Issue(6)：559-569,11.DOI:10.3872/j.issn.1007-385x.2025.06.001
靶向实体瘤CAR-T细胞设计:安全性与通用性提升策略
Design of CAR-T cells targeting solid tumors:strategies for enhancing safety and universality
摘要
Abstract
Chimeric antigen receptor gene-modified T(CAR-T)cell therapy represents an immunotherapeutic approach wherein autologous T cells are genetically engineered ex vivo to express specific chimeric antigen receptors(CARs),expanded,and reinfused into patients to specifically recognize and eliminate tumor cells.Despite substantial efficacy in hematological malignancies,CAR-T cell therapy encounters significant barriers in solid tumors.Immune-related adverse events(irAEs),including cytokine release syndrome(CRS),compromise safety profiles,while tumor-associated antigen(TAA)heterogeneity restricts both single-target CAR-T cell applicability and universal CAR-T cell development.Consequently,breakthrough refinements remain essential for clinical translation in solid tumors.This review examines CAR-T cell therapy for solid tumors,critically evaluating safety and universality enhancement strategies through three core approaches:structural CAR design optimization,universal immune receptor retargeting,and antigen universality augmentation.Each approach undergoes systematic analysis of research pathways,advantages,and limitations,with future trajectories delineated.By synthesizing advances in safety and universal design paradigms,the review aims to establish innovative frameworks for CAR-T cell therapeutic development in solid tumor therapeutics.关键词
实体瘤免疫治疗/嵌合抗原T细胞疗法/脱靶效应/开关CAR-T细胞Key words
solid tumor immunotherapy/chimeric antigen receptor gene-modified T(CAR-T)cell therapy/off-target effect/switchable CAR-T cell分类
医药卫生引用本文复制引用
邱毓灵,廖天艺,刘宝瑞,李茹恬..靶向实体瘤CAR-T细胞设计:安全性与通用性提升策略[J].中国肿瘤生物治疗杂志,2025,32(6):559-569,11.基金项目
国家自然科学基金(No.82272852) （No.82272852）
江苏省杰出青年基金(No.BK20240017) （No.BK20240017）
